Trials / Completed
CompletedNCT07214857
Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,385 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study was to estimate the number of United States (US) adults with and without prior atherosclerotic cardiovascular disease (ASCVD) and diabetes who may be eligible for inclisiran based on US National Health and Nutrition Examination Survey (NHANES) data and inclisiran eligibility criteria from ongoing clinical trials as well as to estimate the number of preventable ASCVD events based on expected risk reductions from the degree of low-density lipoprotein cholesterol (LDL-C) lowering expected from inclisiran. This study used data from the US NHANES 2011-2020 surveys. NHANES is a national survey which collects medical history, laboratory, and medication information from participants of all ages.
Conditions
Timeline
- Start date
- 2024-03-29
- Primary completion
- 2024-10-09
- Completion
- 2024-10-09
- First posted
- 2025-10-09
- Last updated
- 2025-10-09
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07214857. Inclusion in this directory is not an endorsement.